Last reviewed · How we verify
NCT04619433
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
Phase 3 trial testing Camrelizumab;Pemetrexed and Carboplatin; Famitinib; in Non-squamous Non-small-cell Lung Cancer in 48 participants. Terminated before completion.
16 August 2025
Quick facts
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 February 2021 |
| Primary completion | 16 August 2025 |
| Estimated completion | 16 August 2025 |
| Sites | 7 locations across China |
Drugs / interventions tested
- Camrelizumab;Pemetrexed and Carboplatin; Famitinib; — full drug profile →
- Camrelizumab;Pemetrexed and Carboplatin;Placebo — full drug profile →
Conditions studied
- Non-squamous Non-small-cell Lung Cancer — all drugs for Non-squamous Non-small-cell Lung Cancer →
Sponsor
Jiangsu HengRui Medicine Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Non-squamous Non-small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Villaruz LC, Blumenschein GR, Otterson GA, Leal TA. · · 2023 · cited 10× · PMID 36848319 · DOI 10.1002/cncr.34683 -
The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Li T, Li X, Jiang X, Wang C, et al · · 2022 · cited 3× · PMID 36107220 · DOI 10.1007/s00280-022-04474-8
Verify or expand the search:
- PubMed search for NCT04619433
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-squamous Non-small-cell Lung Cancer
Currently open trials in the same condition.
- NCT05403554 — A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers · Phase 1 · recruiting
Other Jiangsu HengRui Medicine Co., Ltd. trials
Trials by the same sponsor.
- NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
- NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
- NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
- NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
- NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04619433 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04619433.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing